Janux Therapeutics Inc (JANX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Janux Therapeutics Inc stock (JANX) is currently trading at $13.56. Janux Therapeutics Inc PS ratio (Price-to-Sales) is 82.49. Analyst consensus price target for JANX is $54.00. WallStSmart rates JANX as Sell.
- JANX PE ratio analysis and historical PE chart
- JANX PS ratio (Price-to-Sales) history and trend
- JANX intrinsic value — DCF, Graham Number, EPV models
- JANX stock price prediction 2025 2026 2027 2028 2029 2030
- JANX fair value vs current price
- JANX insider transactions and insider buying
- Is JANX undervalued or overvalued?
- Janux Therapeutics Inc financial analysis — revenue, earnings, cash flow
- JANX Piotroski F-Score and Altman Z-Score
- JANX analyst price target and Smart Rating
Janux Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Janux Therapeutics Inc (JANX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Janux Therapeutics Inc (JANX) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 2178.00% year-over-year
104.99% of shares held by major funds and institutions
Supporting Valuation Data
Janux Therapeutics Inc (JANX) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 82.5x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Janux Therapeutics Inc (JANX) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth, Institutional Own.. Valuation metrics including Price/Book (0.89) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 2178.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (82.49) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -11.50%, Operating Margin at -1577.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -11.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2178.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
JANX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
JANX's Price-to-Sales ratio of 82.49x trades at a deep discount to its historical average of 541.02x (17th percentile). The current valuation is 98% below its historical high of 5245.54x set in Aug 2021, and 96% above its historical low of 42.04x in Oct 2023. Over the past 12 months, the PS ratio has compressed from ~165.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Janux Therapeutics Inc (JANX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Janux Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 10M with 2178% growth year-over-year.
Key Findings
Revenue growing at 2178% YoY, reaching 10M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 48M in cash.
Free cash flow is -29M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Janux Therapeutics Inc maintain 2178%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.88, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Janux Therapeutics Inc.
Bottom Line
Janux Therapeutics Inc is a high-conviction growth story with revenue accelerating at 2178% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(20 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:11:34 AM
About Janux Therapeutics Inc(JANX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.